Hydroxyurea (HU) has been shown to increase the proportion of fetal hemoglobin (Hb F) in most sickle cell patients. A low dosage regimen of HU increased total hemoglobin (Hb) levels in some thalassemia intermedia patients by preferentially increasing b-globin biosynthesis. We examined the effect of dosage, duration of exposure, and developmental stage at which HU was given on various hematological parameters and signaling pathways. Erythroid cells in two-phase liquid culture were exposed to HU (5 to 100 mM) either as a pulse for 3 days or continuously for 12 days. Low doses of HU (from 0 to 25 mM) increased Hb levels by up to 2.7-fold, and a high dose of HU (100 mM) increased Hb levels when added at days 3-6 of phase II. No significant changes in Hb levels were observed in response to HU during the late stage of phase II culture (>=9-12 days), although there was a significant dose-dependent increase in Hb F levels. HU exposure during days 0-3 of phase II culture increased the number of erythroid colonies to a maximum of 5-fold at 5 mM HU. GATA-1 mRNA was down-regulated at a high dose of HU and GATA-2 was dose-dependently up-regulated over a lower dosage range. Treatment with 100 mM HU dramatically upregulated the death receptor DR-5, caspase 3, and various other genes related to cell cycle control and apoptosis, as determined by cDNA microarray analysis. In contrast, 10 mM HU modestly up-regulated mRNA levels of the early growth response gene (egr-1). Our results suggest that HU exerts concentration-dependent effects on Hb F production and erythropoiesis and that these two effects are mediated by distinct molecular mechanisms. We are currently focusing further clarifying the mechanism of low dose HU on erythropoiesis by studying the Egr-1 signal pathways.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Intramural Research (Z01)
Project #
1Z01DK027001-07
Application #
6983687
Study Section
Medicinal Chemistry B Study Section (MCHB)
Project Start
Project End
Budget Start
Budget End
Support Year
7
Fiscal Year
2004
Total Cost
Indirect Cost
Name
U.S. National Inst Diabetes/Digst/Kidney
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Aerbajinai, Wulin; Zhu, Jianqiong; Gao, Zhigang et al. (2007) Thalidomide induces gamma-globin gene expression through increased reactive oxygen species-mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesis. Blood 110:2864-71
Weatherall, David; Hofman, Karen; Rodgers, Griffin et al. (2005) A case for developing North-South partnerships for research in sickle cell disease. Blood 105:921-3
Lin, Elaina E; Rodgers, Griffin P; Gladwin, Mark T (2005) Hemolytic anemia-associated pulmonary hypertension in sickle cell disease. Curr Hematol Rep 4:117-25
Gladwin, Mark T; Sachdev, Vandana; Jison, Maria L et al. (2004) Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 350:886-95
Vortmeyer, Alexander O; Frank, Stephan; Jeong, Seon-Yong et al. (2003) Developmental arrest of angioblastic lineage initiates tumorigenesis in von Hippel-Lindau disease. Cancer Res 63:7051-5
Wang, Min; Tang, Delia C; Liu, Wenli et al. (2002) Hydroxyurea exerts bi-modal dose-dependent effects on erythropoiesis in human cultured erythroid cells via distinct pathways. Br J Haematol 119:1098-105
Gladwin, Mark T; Shelhamer, James H; Ognibene, Frederick P et al. (2002) Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. Br J Haematol 116:436-44